United Therapeutics (UTHR) Tops Q3 EPS by 1.10, Revenues Beat

United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $3.88, $1.10 better than the analyst estimate of $2.78. Revenue for the quarter came in at $380.1 million versus the consensus estimate of $356.95 million.

"As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "I expect these three launches will set us on the path to revenue growth in the near term."

"We are very pleased with the strong year-over-year growth for both Orenitram and Tyvaso," said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. "Our prostacyclin products are now being used by a larger number of pulmonary arterial hypertension patients in the United States than ever before, as demand has returned to pre-pandemic levels."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• St. Joe Company (JOE) Reports Q1 EPS of $0.24
• First Mid Bancshares, Inc. (FMBH) Tops Q1 EPS by 8c